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Background: In some situations, practice guidelines do not provide firm evidence-based guidance regarding COPD
treatment choices, especially when large trials have failed to identify subgroups of particularly good or poor
responders to available medications.
Methods: This observational cross-sectional study explored the yield of four types of multidimensional analyses to
assess the associations between the clinical characteristics of COPD patients and pharmacological and
non-pharmacological treatments prescribed by lung specialists in a real-life context.
Results: Altogether, 2494 patients were recruited by 515 respiratory physicians. Multiple correspondence analysis
and hierarchical clustering identified 6 clinical subtypes and 6 treatment subgroups. Strong bi-directional
associations were found between clinical subtypes and treatment subgroups in multivariate logistic regression.
However, although the overall frequency of prescriptions varied from one clinical subtype to the other for all types
of pharmacological treatments, clinical subtypes were not associated with specific prescription profiles. When
canonical analysis of redundancy was used, the proportion of variation in pharmacological treatments that was
explained by clinical characteristics remained modest: 6.23%. This proportion was greater (14.29%) for
non-pharmacological components of care.
Conclusion: This study shows that, although pharmacological treatments of COPD are quantitatively very well
related to patients’ clinical characteristics, there is no particular patient profile that could be qualitatively associated
to prescriptions. This underlines uncertainties perceived by physicians for differentiating the respective effects of
available pharmacological treatments. The methodology applied here is useful to identify areas of uncertainty
requiring further research and/or guideline clarification.
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reproduction in any medium, provided the orCOPD is a major cause of disability and premature
death worldwide [1]. Smoking cessation is the only way
of modifying the natural history of the disease, while
other pharmacological and non-pharmacological inter-
ventions have the potential for reducing its burden in
terms of dyspnea, exercise performance, exacerbations
and quality of life [1-5]. Recently, large long-term trials
also provided somehow encouraging (although not to-
tally conclusive) results on the possible effects of fixed
combinations (namely, salmeterol + fluticasone), long-
acting beta2 agonists (LABA, namely salmeterol) and
long-acting antimuscarinic agents (LAMA, namelyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[2,3,6,7]. In parallel, during the last decade many studies
underlined the multi-component character of the disease
[8] and rehabilitation was found highly effective at fight-
ing the decrease in exercise performance and daily activ-
ity at all disease stages [9].
But the complexity of the disease implies that there is
no unique phenotype: for instance, the weight of comor-
bidities or the frequency of exacerbations vary from one
patient to another [8,10,11], as well as the respective
contributions of airways disease and emphysema [12].
This area has been the topic of several recent studies
aiming at identifying clinically relevant phenotypes or
developing prognostic scores [13,14]. The use of some
clinical characteristics has been advocated to guide treat-
ment choices in COPD: FEV1 is the main cited criterion,
together with the repetition of exacerbations and the
level of dyspnea [1]. Some algorithms propose rules to
modulate treatments when the disease severity and im-
pact increase [15]. However, while LAMA, LABA or
ICS + LABA combinations have been shown to relieve
dyspnea, decrease exacerbations frequency and improve
quality of life [2,3], studies have been unable to clearly
identify subgroups of subjects responding particularly
well to a given medication [16-20]. For instance, in one
of the above-mentioned clinical trials, a favourable effect
of tiotropium on lung function decline was found only
in GOLD 2 patients, suggesting the possibility of a better
responding subgroup; however, there was no interaction
between symptomatic effects and patients’ characteristics
[2]. Thus, in many situations several therapeutic options
are available, without clear-cut differentiation in terms
of target populations.
Finally, several studies including some performed in
France found that treatment choices by physicians differ
sometimes markedly from guidelines recommendations,
e.g., regarding the use of inhaled corticosteroids [21-23].
For these treatments as well as for choices between
bronchodilators, the criteria on which physicians rely are
quite unclear.
This observational study was performed to identify the
patients characteristics associated with treatment choices
in COPD patients visiting a respiratory physician at
stable state. More generally, it aimed at exploring
whether multidimensional analyses performed with no a
priori hypothesis could link some typologies of clinical
characteristics to some typologies of treatments, using
data that are readily available in routine practice.
Methods
Study design
This was an observational study of COPD patients
recruited by 515 respiratory physicians. Each of them
was asked to recruit the first 5 consecutive patients withCOPD (GOLD diagnostic criteria) who visited him/her
at stable state and agreed to participate. All GOLD
stages could be enrolled, as well as at-risk patients (i.e.,
presence of chronic bronchitis with normal lung func-
tion, previously GOLD stage 0). Patients were not
included if they reported an exacerbation during the last
4 weeks, when no lung function data was available dur-
ing the past 2 years or when they suffered from a
significant comorbidity compromising the short-term
prognosis. All patients provided informed consent before
inclusion and the study was approved by the ethics com-
mittee of Versailles (France).
Collected data
The following data were recorded: socio-demographic
characteristics, risk factors (active and passive smoking,
occupational exposures), history of COPD (year of first
symptoms and year of diagnosis), comorbidities, number
and severity of exacerbations, most recent lung function
data, symptoms (cough, sputum production, MRC dys-
pnea grade) using questions derived from the European
Communicty Respiratory Health Survey [24], usual
maintenance pharmacological and non-pharmacological
treatments, yearly number of visits to GPs and chest
physicians, investigations performed during the previous
year. Exacerbations were defined as an increase in cough
and/or sputum production and/or dyspnea during at
least 48 hours and requiring a change in treatment (i.e.,
at least an increase in the dose of bronchodilators).
Their severity was classified as mild (self-managed
change in treatment), moderate (requiring a visit to a
physician), severe (hospitalisation in a medical ward) or
very severe (hospitalisation in an intensive care unit).
Statistical analysis
The planned sample size was set to 2400 patients to ob-
tain a 2% precision in the prevalence estimate of a pa-
tient characteristic that is present in about 50% of the
population. A two-step process was followed, first identi-
fying typologies of patients and treatments, then explor-
ing their relationships.
Two analyses were used to find typologies of patients on
the one hand and typologies of treatments on the other:
the multiple correspondence analysis (MCA) and the
ascending hierarchical complete linkage clustering analysis
(AHCLCA)[25,26]. MCA allows mapping patients’ charac-
teristics or treatments in a reduced space according to
their deviation from independence (association or mutual
exclusion). Clustering is based on the distance between
variables, which is equal to 1 minus the correlation. This
method forces the inclusion of all variables in a given
group. As a consequence, small groups are constituted of
positively related variables, while larger groups may pool
together variables that may be unrelated to each other or
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were combined to find a typology.
Once groups of patient characteristics and groups of
treatments were defined, multiple logistic regression was
used to assess (i) associations between each clinical sub-
type and the 6 treatment subgroups and (ii) associations
between each treatment subgroup and the 6 clinical sub-
types, to identify the clinical subtype to which a given
treatment type is preferentially prescribed or in which it
is underprescribed. These two approaches should pro-
vide convergent but not exactly similar results because
the odds ratios measuring associations between clinical
subtypes and treatment subgroups are not adjusted on the
same set of covariates (adjustment on other treatment
subgroups in one case and on other clinical subtypes in
the other). Canonical analysis of correspondence (CAC)
[25,26] and more precisely principal component analysis
(PCA) with respect to instrumental variables [27] was
then used to map treatment variables and patient charac-
teristics in a reduced space and identify (without any clus-
tering) which patient characteristics are associated to
which treatments. Two canonical redundancy analyses
were performed: the first one with prescribed COPD
medication including oxygen therapy as response variables
(16 variables), the second with other (i.e., non-pharmaco-
logical) COPD treatments and patient follow-up variables
(8 variables: number of antibiotic courses, homeopathy,
flu vaccine, pneumococcal vaccine, chest physiotherapy,
frequency of visits to respiratory physician, frequency of
visits to general practitioners and frequency of lung func-
tion tests).
More details on these methods can be found in the
electronic supplementary material.
Results
Population and treatments characteristics
About 3000 respiratory physicians (i.e., all French re-
spiratory physicians) were contacted; 515 accepted to
participate and were compared to a random sample
of 245 non-participating physicians: no significant
difference was found in terms of type of clinical
practice (general hospital, university hospital, private
practice). The 515 participating physicians were har-
moniously distributed on the whole French mainland
territory. They recruited 2494 patients, among whom
recent lung function data was unavailable in only 10
(protocol deviations). The general characteristics and
treatments of the population are summarized in
Table 1.
Definition of clinical subtypes by MCA, clustering and
their combination
Detailed results of MCA and cluster analysis of clinical
subtypes are provided in the electronic supplementarymaterial. Altogether, MCA allowed defining 9 groups
within the first four interpretable axes, while 7 clusters
were identified from clustering. Putting all these results
together lead to define 6 clinical subtypes (Table 2). It
has to be noted that these subtypes are not exclusive: for
instance, a given patient may belong to subtype 4
(women) and subtype 1 (mild severity).Treatment subgroups defined by MCA, clustering and
their combination
Detailed results of MCA and cluster analysis of treat-
ment characteristics are provided in the electronic sup-
plementary material. Briefly, again four axes of the
correspondence analysis were interpretable and MCA
allowed defining 5 groups while clustering found 6 clus-
ters. The combination of ordination and clustering lead
to distinguish 6 treatment subgroups (Table 3). Oral cor-
ticosteroids belong to treatment subgroup 1 (nebulised
treatments) because they can be associated with (i.e.,
they are not negatively related to) nebulised drugs. MCA
and clustering show that treatments subgroups 1 and 2
(fixed ICS + LABA combinations) are usually mutually
exclusive (opposite position on axis 1, and linkage at a
negative correlation). Like clinical subtypes, treatment
subgroups are not exclusive and two types of treatments
may therefore be prescribed to the same patient.Relationship between clinical subtypes and treatment
subgroups
Odds ratio (OR) estimated by the 12 multivariate logistic
regressions are presented in Table 4. Each row indicates
whether the clinical subtype is overrepresented (OR > 1)
or under-represented (OR< 1) in the prescriptions of
each treatment type. Each column indicates if the treat-
ment type is preferably prescribed (OR> 1) or preferably
avoided (OR< 1) in patients of a given clinical subtype.
Odds ratios within the same cell of the table are slightly
different because they are not adjusted on the same set
of covariates (see the methods section). Overall, the
results show that associations are more quantitative than
qualitative in that all treatment types are significantly
less prescribed to less severe patients (i.e., patients sub-
type 1) and more prescribed to the most severe (patients
subtype 3). More specific associations were as follows:
fixed combinations (treatment subgroup 2) are signifi-
cantly more prescribed to elderly patients (patients sub-
type 6) while nebulized treatments (treatment subgroup
1) are significantly less prescribed to these patients. Vac-
cines (treatment subgroup 6) are more prescribed in
patients with symptoms of chronic bronchitis (subtype
5) and respiratory support (treatment subgroup 4) is sig-
nificantly related to clinical subtype 2 (overweight smo-
kers with comorbidities).
Table 1 Patients, investigations, follow-up and treatments characteristics
N=2494 Mean± SD or%
Age (years) 67.0 ± 10.6
Male (%) 78%
Body mass index (kg/m2) 25.84 ± 5.17
Smokers / ex-smokers 25.6% / 62.4%
Chronic bronchitis without airflow obstruction / COPD 23.7% / 76.3%
(GOLD stage): 1 / 2 / 3 / 4 2.9% / 29.7% / 26.1% / 17.6% /
FEV1 (L/sec) 53.1 ± 19.6
Duration of chronic bronchitis / COPD (years) 8.0 ± 7.8
Chronic cough / sputum production 70.5% / 72.2%
Chronic cough with sputum production by GOLD stage in COPD patients: GOLD 1/2/3/4 62.0% / 71.9% / 72.4% / 76.4%
Modified Medical Research Council dyspnea grade: 1 / 2 / 3 / 4 / 5 14.2% / 30.3% / 30.5% / 16.2% / 6.1%
At least one exacerbation during the last 12 months 86.3%
Number of exacerbations per year
-Mild / moderate (oral corticosteroids or antibiotics) 1.4 ± 2.3 / 1.6 ± 1.7
-Severe (hospitalization) / very severe (intensive care unit) 0.3 ± 0.8 / 0.0 ± 0.2
Comorbidities
-CHD / CHF / RVF 14.9% / 6.5% / 7.2%
-Asthma / bronchiectasis / sleep apnea syndrome 11.9% / 6.3% / 8.6%
-Depression 7.9%
Investigations and follow-up during the past 12 months
-Arterial blood gases / EKG 70.0% / 68.8%
-CT-scan / echocardiography 61.6% / 50.6%
-Sleep oximetry / polysomnography 23.2% / 15.4%
-6MWT 27.9%
Visits to respiratory physicians / GPs 2.6 ± 1.7 / 6.7 ± 4.1
Treatments
-ICS / Fixed ICS + LABA combinations 22.8% / 51.5%
-SABA / SABA+ SAMA 34.9% / 29.9%
-LABA / LAMA 26.6% / 17.0%
-Theophylline / oral corticosteroids 8.3% / 4.5%
-LTOT / LTNIV 16.6% / 4.8%
-Influenza / pneumococcal vaccines 81.2% / 58.2%
-Rehabilitation during the last 2 years 26.9%
CHD: coronary heart disease; CHF: congestive heart failure; RVF: right ventricular failure; EKG: electrocardiogram; 6MWT: 6-minutes walk test; GP: general
practitioner; ICS: inhaled corticosteroids; SABA/LABA: short/long-acting beta-agonists; SAMA/LAMA: short/long-acting anticholinergics; LTOT/LTNIV: long-term
oxygen therapy / non-invasive ventilation.
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and pharmacological and non-pharmacological
treatments
Only 6.23% of variations in the use of pharmacological
treatments are explained by patient characteristics as
described by 6 families of variables: Table 5 shows the
components of each of these families and the percentage
of treatment variations that it explained. Altogether, the
described associations are vague and reflect trends or ten-
dencies rather than tight relations. Significant explanatoryvariables for components of care other than medications
are shown in Table 6. Altogether, 14.29% of variations of
these components of care are explained by patient
characteristics.
Discussion
In this large sample of COPD patients cared for by re-
spiratory physicians, several approaches to factorial ana-
lysis were used in a step by step manner to identify
associations between administered treatments on the
Table 2 Clinical subtypes identified by combination of multiple component and clustering analyses, and their relations
with treatment subgroups
Clinical subtypes Description, frequency and associated treatment type
1 : Exposed but not severely impaired patients Exposed to tobacco smoke or occupational smokes, toxic gaz or dust.
No severe airflow obstruction (VEMS> 60%). MRC grade 0 (maximum MRC grade = 2).
9.62%* of patients met the first three conditions.
Patients of this clinical subtype are underrepresented in all treatment subgroups and
particularly respiratory support (treatment group 4: OR= 0.198). All treatment types are
less prescribed to this clinical subtypes and particularly respiratory support
(treatment subgroup 4: OR = 0.255).
2 : Overweight smokers with high blood pressure and
other comorbidities
Sleep apnea. Men. Robust stature (weight >80 kg). Current smokers.
Underwent polysomnography. High blood pressure. Large variety of other
comorbidities. Rather mild or moderate MRC grade.
6.50%* of patients met the first three conditions.
Patients of this clinical subtype are overrepresented among prescriptions of
respiratory support (treatment subgroup 4: OR = 3.625) and
underrepresented among prescriptions of vaccines
(treatment subgroup 6: OR = 0.581).
3 : Severe airflow obstruction Severe dyspnea (MRC grade 4 or 5). Low FEV1 (< 50%) and FVC. Chronic right
ventricular failure. Emphysema. Many investigations performed or prescribed including
lung CT-scan, bronchoscopy, DLCO, 6-min walking test, sleep oxymetry, arterial blood
gases, exercise testing, echocardiography, EKG, lung scintigraphy.
16.06%* of patients met the first two conditions.
Patients of this clinical subtype are overrepresented in all treatment subgroups and
particularly respiratory support (treatment subgroup 4: OR = 6.214). All treatment
subgroups are more prescribed to this clinical subtype, and particularly respiratory
support (treatment subgroup 4: OR= 7.381).
4 : Women Women. Small stature (< 66 kg, < 165 cm). Small respiratory capacity (FEV1 < 1 l,
FVC< 2 l). 60 years old or more. MRC grade can be severe. Often living alone. Possibly
depressive. Living in town. Associated asthma is possible. Were prescribed reversibility
testing.
12.70% *of patients met the first three conditions.
Patients of this clinical subtype are not significantly overrepresented or
underrepresented in any treatment subgroup and no treatment subgroup is
significantly more (or less) prescribed to this clinical subtype
(no special treatment for women).
5 : Patients with symptoms of chronic bronchitis Chronic cough and sputum production, chronic bronchitis. Fibrous or cavity sequelae
and bronchiectasis in some patients. Not strongly related to MRC grade but rather
moderate.
67.07%* of patients met the first three conditions.
Patients of this clinical subtype are not significantly overrepresented or
underrepresented in any treatment subgroup except for vaccines (type 6: OR= 2.210)
and no treatment subgroup except for type 6 is significantly more (or less) prescribed
to this clinical subtype..
6 : Elderly patients with cardiovascular comorbidity Age> 75 years. Heart diseases: heart failure, ischemic heart disease or other
cardiovascular diseases.Not strongly related to MRC grade but rather moderate.
High blood pressure. Possible peripheral artery disease and cancer.
11.06%* of patients met the first and at least one of the 3 other conditions.
Patients of this clinical subtype are significantly underrepresented in nebulised
treatment (treatment subgroup 1: OR= 0.686) and overrepresented in fixed
combinations (treatment subgroup 2: OR= 1.335) and vaccines
(treatment subgroup 6: OR = 1.335). Nebulised treatments are significantly less
prescribed to this clinical subtype. Fixed combinations and vaccines are significantly
more prescribed to these patients.
Associated treatment subgroups (see Table 3) are those obtained through logistic regressions (see Table 4).
* The sum of percentages is larger than 100% because clinical subtypes are not exclusive. For example the same patient may belong to subtype 1 and 6.
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Table 3 Treatment subtypes identified by combination of multiple component and clustering analyses
Treatment subgroups Description, frequency
1: Nebulised treatments Nebulised anticholinergics and/or beta2 agonists. Less frequently, nebulised
corticosteroids.
One of the first two treatments was prescribed to 45.55% of patients.
2: Fixed combinations Combinations of long acting beta 2 agonist and corticosteroids.
These combinations were prescribed to 51.44% of patients.
3 : LABA and inhaled corticosteroids prescribed separately LABA and inhaled corticosteroids, co-prescribed in 91.2% of patients who
receive one and/or the other outside of a fixed combination.
Such “separate associations” were prescribed to 16.03% of patients.
4: Non-invasive ventilation and oxygen therapy Ventilation or oxygen therapy. Respiratory support may be
prescribed with respiratory rehabilitation.
One of the first two therapies was prescribed to 18.71% of patients.
5: Fixed combinations of short-acting anticholinergic and β2 agonist These treatments are not prescribed in patients who receive long acting
anticholinergics. Prescription of a fixed combination of LABA and ICS is
possible and independent (neither association nor exclusion).
These fixed combinations were prescribed to 29.85% of patients.
6: Flu and pneumococcal vaccines Flu or pneumococcal vaccines and antibiotics, sometimes associated with
chest physiotherapy.
At least one of the two first vaccines and antibiotics were prescribed to
39.83% of patients.
Table 4 Multivariate logistic regressions: Odds ratio for associations between each clinical subtype and treatment
subgroups (first line of each cell in a row) and each treatment subgroup and clinical subtypes
(second line of each cell in a column, in italic)























0.6113 0.7131 0.5811 0.1984 0.5922 0.5753




0.7810 0.9070 0.8910 3.6254 1.0600 0.5812




1.6363 1.6053 1.5801 6.2144 1.3821 1.6063
1.6834 1.4553 1.2070 7.3814 1.3812 2.0954
Clinical type 4
Women 1.1420 0.9520 1.2930 0.8210 1.2500 1.1050




1.1160 0.9860 0.8680 1.1170 1.0950 2.2104





0.6862 1.3351 1.0220 1.3080 0.9540 1.4412
0.7331 1.3231 0.8990 1.2000 1.0870 1.3511
All models included the 6 treatment or clinical subtypes as covariates. Figures in bold are significantly different from 1 and exponent indicates the class of
p values of the log-likelihood test: 0 for p > 0.05, 1 for p ≤ 0.05, 2 for p < 0.01, 3 for p < 0.001 and 4 for p < 0.0001.
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Table 5 Explanation of the overall treatment variation by 6 families of clinical variables
Family Selected variables Adjusted R2 P value
Socio-demographics stature, age, lifestyle (living alone,. . .), 0.0047 0.001
History of COPD and comorbidities history of right ventricular failure, emphysema, sleep apnea,
asthma, dyspnea, chronic sputum production, ischemic heart disease.
0.01998 0.001
Symptoms the days of visit dyspnea (MRC), chronic bronchitis 0.02515 0.001
Lung function FEV1, FEV1%, FVC, 0.02120 0.001




(d. stands for done and p. for prescribed)
sleep oxymetry d., walking test d., arterial blood gases d., scintigraphy d.,
polysomnography d., ECG d., VO2max d., VO2max p., 6MWT p., DLCO p.,
scintigraphy p., EKG p.
0.03927 0.001
The order of variables is the order of their contribution to the explanation of the variation of COPD treatments. d.: done; p.: prescribed.
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multiple correspondence and cluster analyses allowed
identification of sufficiently robust clinical and treatment
subgroups. Then canonical analysis of redundancy showed
that the fraction of variation in pharmacological treat-
ments explained by patient characteristics was small
(6.23%) and half that observed for non-pharmacological
treatments. This approach appears useful to identify areas
of uncertainty in prescription choices by physicians.
Strengths and limitations of the study
Using factor analyses was justified primarily by (i) the
large number of patients characteristics and possible ther-
apies as well as (ii) the known wide overlap between
GOLD stages of airflow obstruction for most clinical vari-
ables used to describe patients (such as dyspnea or exacer-
bation frequency), which makes it difficult to identify
subtypes using conventional analysis. Factor analysis is ba-
sically a descriptive approach that summarizes associa-
tions without any a priori hypothesis. Indeed, it confirmed
that many factors other than FEV1 add to the description
of the population: risk factors, symptoms (chronic bron-
chitis, dyspnea), comorbidities, demographics (age, gen-
der) and anthropometric characteristics (weight) are also
important contributors to characterization. The mainTable 6 Explanation of overall variation in non-pharmacologi
variables
Family Selected variables
Socio-demographics age, weight, town, gender
History of COPD and comorbidities emphysema, chronic sputum
right ventricular failure, bronc
asthma, cough, depression, he
Symptoms the days of visit dyspnea (MRC), chronic bronc
Lung function FEV1, FEV1%, reversibility testin
Exacerbations and smoking status number of exacerbations, cur
occupational exposure to dus
Investigations
(d. stands for done and p. for prescribed)
6MWT d., CT-scan d., echoc
scintigraphy. d., nocturnal oxy
gases p., EKG d., DLCO p., fibe
The order of variables is the order of their contribution to the explanationof the valimitation of these methods is their high dependency on
active variables that participate to the construction of
axes. Addition or subtraction of some variables (character-
istics) may change the typology. Moreover, the choice of
characteristics constituting one group (subtype) is not
fully objective (preferential collection of characteristics
that are believed to be relevant). Thus, the choice of
recorded variables may be questioned: some variables that
may predict treatment choices may have been omitted
when building the case-report form; this could participate
to explain why clinical characteristics as a whole were
poorly associated to treatment subgroups. However, it
must be outlined that the selection of collected data
included all patients and disease characteristics that are
routinely accessible to any practitioner: therefore, if some
additional information was lost (e.g., degree of emphysema
on CT-scan, lung volumes or diffusion capacity, character-
istics of airway inflammation as measured in induced spu-
tum), it would not be relevant in routine clinical practice.
The large sample size of the present study provides a
good power for detecting associations (80% chance of
detecting a true correlation of 0.057 and 70% chance of
detecting a true correlation of 0.05) and therefore allows
considering that, if some real relations are not detected,
they would be very small and of no clinical relevance.cal care (other treatments and follow up) by 6 families of
Adjusted R2 P value
0.02517 0.001
production, dyspnea, history of








ardiography d., arterial blood gases d.,
metry d., 6MWT p., arterial blood
roptic bronchoscopy d., DLCO d., EKG p.
0.07245 0.001
riation of COPD treatments.
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factors completely different from those recorded in our
study. We believe that this last explanation is rather un-
likely since virtually all routinely collected clinical and
lung function characteristics of COPD were assessed.
Another limitation to be addressed relates to the stat-
istical methods used for factorial analyses: a group of
redundant characteristics (information) may be well
represented because of their association (redundancy)
while an independent clinically relevant information
could be lost in the blank noise and not be well repre-
sented by the interpretable axes. The risk of such an
event is minimized by the use of 3 different statistical
approaches that search for associations through different
procedures. For example, cluster analysis does not lose
any variable in the blank noise.
We did not include the new GOLD classification
(A-B-C-D) [1] into the analyses, Indeed, our purpose
was to study the relationship between treatment deci-
sions and patients’ characteristics with no a priori hy-
pothesis rather than to test the relations between
treatments and already defined patients subgroups such
as those proposed in the new GOLD document. Interest-
ingly, the variables that participate most to the definition
of the patients subgroups identified by cluster analyses ac-
tually do not fit with those used in the GOLD A-B-C-D
classification (see Table 2). Therefore, this classification is
quite unlikely to by closely related to treatment choices.
Finally, the new GOLD classification was not available
when the study was performed, and could therefore not
be used per se for treatment choices by physicians.
While care for COPD is quite heterogeneous in Europe,
the present study was performed in only one European
country where local guidelines (taking into account the
GOLD documents) exist and have been widely dissemi-
nated, Therefore, it might have been hypothesized that
practice would be more homogeneous than in a multi-
national survey. Even though, it remained difficult to de-
termine how physicians make their choices.
Associations between treatments and clinical
characteristics
There appeared to be separate gradients in the use of
ICS+LABA, short acting bronchodilators, nebulised treat-
ments and oral corticosteroids, and respiratory support.
Such data suggest that several independent (at least in
part) factors influence treatment choices. The very low
variation of pharmacological treatments explained by clin-
ical subtype is in line with data from other studies, which
showed that the treatment of COPD is notably heteroge-
neous, either for stable disease or exacerbations. This can
be due to several factors. Firstly, some physicians may
have their own “specific” and “patient-independent” thera-
peutic habits. This could have prevented us from detectingan overall strategy since the investigator effect could not
be taken into account due to the too low number of
patients per physician. Secondly, the investigator’s thera-
peutic strategy may depend mostly on what was already
prescribed to the patient in the past. This might not be
detected since this was a cross-sectional study, providing
only a snapshot of the situation at a given time and pre-
venting from capturing the evolution of the treatment
strategy over time. In addition, we did not record treat-
ment changes that were decided during the visit, which
would have allowed us to detect how new prescriptions
were influenced by previous treatments. Thirdly and most
importantly, physicians may consider that currently avail-
able treatments are not markedly different in terms of effi-
cacy and safety profile. This would be in accordance with
the impossibility to identify well-defined subgroups of
responders or non-responders in recent major treatment
trials [16-20]. This can be explained in two ways: either
recorded patients characteristics are not the correct pre-
dictors of response, or response is not adequately defined
(e.g., by FEV1, which is used in most studies). Indeed,
available guidelines are quite vague about clinical criteria
that may allow to choose, e.g., between available classes of
inhaled bronchodilators. This relates to the lack of convin-
cing evidence on the superiority of any treatment in well-
defined subgroups, even in large randomised controlled
trials [16,17]. Considering these observations, there is a
clear need for further research on phenotypes and predic-
tors of response to treatments.
Even though, efforts should also be directed at improv-
ing adherence of physicians to guidelines and under-
standing the determinants of their therapeutic choices.
Dissemination is obviously required but also clearly in-
sufficient to ensure wide guidelines implementation and
appropriate treatment use. Barriers have to be identified
and may relate to guidelines themselves (when unclear
or too difficult to implement) but also to physicians (iner-
tia,lack of awareness, familiarity, agreement, self-efficacy,
outcome expectancy, ease of prescription, anticipated
drawbacks), patients (underlying the importance of taking
their preferences into account) or healthcare systems (“ex-
ternal barriers”). These aspects have been extensively
reviewed elsewhere, especially in a 2005 Canadian Wok-
shop focused on asthma and COPD [28].
However, it must also be underlined that explaining
6.23% of treatment variations by patients characteristics
is not amazingly low compared to results obtained in
other therapeutic areas: in most studies of the same kind
with other medications available on the market (e.g.,
anti-depressants), less than 10% of treatment choices
can be attributed to specific patients characteristics.
Thus, even if the percentage of explained variation is not
large, relationships were found and the two main criteria
for the choice of treatments according to current
Roche et al. BMC Pulmonary Medicine 2012, 12:39 Page 9 of 10
http://www.biomedcentral.com/1471-2466/12/39guidelines, FEV1 and exacerbations, were confirmed as
predictors of treatment choices in MCA and canonical
analyses. Moreover, it was possible to go further and find
far more associations with other factors including dyspnea
and comorbidities. Finally, it must be kept in mind that in-
dividual treatment responses were not recorded in the
study. Therefore, our findings do not refute the hypothesis
of specific phenotypes based on response to treatments.
Actually, we cannot test this hypothesis due to the cross-
sectional nature of the study. While we can conclude that
the choice of a given treatment does not markedly relate
to patients’ characteristics at a given time-point, we cannot
exclude that it relates to improvements reported by the
patient or recorded by the physician, following the first
prescription of this treatment.
The % of variation of non pharmacological treatments
that is explained by clinical characteristics of patients
represents more than twice the amount of variation of
medications for COPD that was explained by these char-
acteristics. Components of care other than medications
are thus more dependent upon patient characteristics
or/and more stereotyped across physicians than medica-
tion strategy, which may suggest greater confidence in the
specific (or differentiated) effects of non-pharmacological
treatments. Moreover, clinical variables explaining non-
pharmacological treatments are not strictly the same as
for medications, which reflects the use of different patient
characteristics for adjusting different components of care.
Conclusions
In conclusion, it is clear from this study that, at present,
patients’ characteristics are not an overwhelming factor
for explaining the therapeutic strategy in stable COPD.
This suggests the need to rationalize treatment choices.
To achieve this, it would be useful to increase our know-
ledge on clinical subtypes and their association with treat-
ment responses. Such information could be obtained from
factor analyses applied on large databases, observational
studies and large long-term therapeutic trials: this type of
analyses appears capable of identifying patients and
treatments subtypes and analysing their relationship.
Altogether, the methods used here allow identification of
areas of uncertainties in prescriptions and may provide
opportunities to identify responders both in clinical trials
and in the real life.
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